UNSPSC 51132220: Acetaminophen/pamabrom/pyridoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132220 Acetaminophen/pamabrom/pyridoxine is a Commodity code, but the recent solicitation activity tagged under it shows minimal direct alignment with this specific combination product. The three opportunities posted since April 2026 reflect broader pharmaceutical and over-the-counter procurement: Seminole County, Florida's IFB for naloxone and drug deactivation systems (a harm-reduction and emergency response product category), Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription fulfillment models, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across state and local government facilities. State and local buyers using this code appear to be pursuing pharmaceutical suppliers through multiple channels—competitive sealed bidding, information-gathering RFIs to assess market capability, and cooperative purchasing agreements—rather than narrow sourcing of a single branded or multi-ingredient formulation.

The issuing-body mix spans state health agencies (Texas HHS), county public health departments (Seminole County), and multi-state cooperative purchasing programs administered by state procurement offices (MMCAP through Minnesota Department of Administration). Geographic activity centers on Florida, Texas, and Minnesota in the recent record, with MMCAP's multi-state footprint extending to Oregon and other participating jurisdictions. The Seminole County IFB (closed July 26, 2023, for quarterly naloxone and drug deactivation systems deliveries) and the MMCAP RFP (due March 26, 2026, for generic pharmaceuticals and OTC products through three authorized wholesalers with a July 1, 2026 effective date and two-year initial term) represent the most concrete procurement opportunities. The MMCAP procurement is the largest in scope, requiring vendors to provide fixed or net pricing, maintain compliance with cGMP and Drug Supply Chain Security Act regulations, hold $5 million commercial general liability coverage, and pay a 3 percent administrative fee on purchases; MMCAP awards sole, dual, or multi-award contracts and penalizes late reporting or onboarding failures at $200 to $1,500 per incident.